TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35820779

Group type: EXPERIMENTAL
Intervention: Algorithm for NASH using PLIN2 mean fluorescence intensity (MFI) combined with waist circumference, triglyceride, alanine aminotransferase (ALT), and presence/absence of diabetes as covariates
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Algorithm including RAB14 MFI, age, waist circumference, high-density lipoprotein cholesterol, plasma glucose, and ALT levels as covariates to predict liver fibrosis
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Proposed novel liquid biopsy
Number of subjects: 250
Study: 35820867

Group type: EXPERIMENTAL
Intervention: PREVENT score
Number of subjects: 5250

Group type: COMPARATOR
Intervention: CAN score
Number of subjects: 5250
Study: 35820889

Group type: EXPERIMENTAL
Intervention: APG-2449
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: APG-2449 in combination with paclitaxel
Number of subjects: 0
Study: 35820917

Group type: EXPERIMENTAL
Intervention: Mental health training integration in TB services
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Screening for mental health conditions in TB patients
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Qualitative data collection through focus groups and interviews
Number of subjects: 162
Study: 35821349

Group type: EXPERIMENTAL
Intervention: GnRH antagonist (GnRH-ant) protocol
Number of subjects: 0

Group type: COMPARATOR
Intervention: GnRH agonist (GnRH-a) protocol
Number of subjects: 0
Study: 35821380

Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept (IVT-AFL) treatment intervals of < 8 weeks
Number of subjects: 269

Group type: COMPARATOR
Intervention: Non-injection-intensive patients
Number of subjects: 269
Study: 35821806

Group type: EXPERIMENTAL
Intervention: Uthever (NMN Supplement)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 35821820

Group type: EXPERIMENTAL
Intervention: Combined Vitamin D, Omega-3 Fatty Acids, and a Simple Home Exercise Program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 35821844

Group type: EXPERIMENTAL
Intervention: Glycine and N-Acetylcysteine supplementation (GlyNAC) at low dose (2.4 g/day) for 2 weeks
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Glycine and N-Acetylcysteine supplementation (GlyNAC) at medium dose (4.8 g/day) for 2 weeks
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Glycine and N-Acetylcysteine supplementation (GlyNAC) at high dose (7.2 g/day) for 2 weeks
Number of subjects: 114
Study: 35822301

Group type: EXPERIMENTAL
Intervention: Systemic inflammation biomarkers (CRP, IL-6, procalcitonin [PCT])
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Systemic inflammation biomarkers (CRP, IL-6, PCT)
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: CRP, IL-6, PCT levels
Number of subjects: 215
Study: 35822945

Group type: EXPERIMENTAL
Intervention: PrEP initiation
Number of subjects: 2550

Group type: EXPERIMENTAL
Intervention: PrEP refill at 1 month
Number of subjects: 2550

Group type: EXPERIMENTAL
Intervention: PrEP persistence at 6 months
Number of subjects: 2550

Group type: EXPERIMENTAL
Intervention: PrEP restart after gap
Number of subjects: 2550

Group type: EXPERIMENTAL
Intervention: Average PrEP dosing
Number of subjects: 2550

Group type: EXPERIMENTAL
Intervention: HIV seroconversions
Number of subjects: 2550
Study: 35829629

Group type: EXPERIMENTAL
Intervention: Chemotherapy and radiation therapy
Number of subjects: 1
Study: 35829723

Group type: EXPERIMENTAL
Intervention: Bleeding events
Number of subjects: 620

Group type: EXPERIMENTAL
Intervention: Thrombotic events
Number of subjects: 620

Group type: EXPERIMENTAL
Intervention: Both bleeding and thrombosis
Number of subjects: 620

Group type: EXPERIMENTAL
Intervention: Intracranial hemorrhage
Number of subjects: 620

Group type: EXPERIMENTAL
Intervention: Ventilation duration before ECMO ≥ 7 days
Number of subjects: 620

Group type: EXPERIMENTAL
Intervention: Length of ECMO support
Number of subjects: 620
Study: 35829748

Group type: EXPERIMENTAL
Intervention: Novel nanobody without a hexahistidine (His)
Number of subjects: 0
Study: 35829780

Group type: EXPERIMENTAL
Intervention: Rituximab combined with intensive chemotherapy (group R1)
Number of subjects: 419

Group type: EXPERIMENTAL
Intervention: Rituximab combined with intensive chemotherapy (group R2)
Number of subjects: 419

Group type: EXPERIMENTAL
Intervention: Rituximab combined with intensive chemotherapy (group R3)
Number of subjects: 419

Group type: EXPERIMENTAL
Intervention: Rituximab combined with intensive chemotherapy (group R4)
Number of subjects: 419

Group type: COMPARATOR
Intervention: Historical data (control group)
Number of subjects: 419

Group type: EXPERIMENTAL
Intervention: Rituximab (toxicities)
Number of subjects: 419
Study: 35829947

Group type: EXPERIMENTAL
Intervention: Mandibular advancement splint (MAS)
Number of subjects: 17
Study: 35830223

Group type: EXPERIMENTAL
Intervention: 1-km outdoor cardio trekking test trail
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: 8-km hiking trails
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Treadmill test in the laboratory
Number of subjects: 144
Study: 35830239

Group type: EXPERIMENTAL
Intervention: C3-Cloud collaborative computer platforms for patients and multidisciplinary team members
Number of subjects: 3
Study: 35830245

Group type: EXPERIMENTAL
Intervention: Brothers Saving Brothers (BSB) motivational interviewing behavioral intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Kings intervention (adapted BSB intervention)
Number of subjects: 0
Study: 35830251

Group type: EXPERIMENTAL
Intervention: Peer-led nutrition and exercise intervention over 12 weeks
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Peer-led nutrition and exercise intervention
Number of subjects: 20
Study: 35830343

Group type: EXPERIMENTAL
Intervention: ICF core set for post-acute musculoskeletal conditions
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Comprehensive ICF Core Set for Subacute Musculoskeletal Conditions
Number of subjects: 84
Study: 35830435

Group type: EXPERIMENTAL
Intervention: Predictive model based on clinical, ultrasonographic, biophysical and biochemical variables
Number of subjects: 429

Group type: EXPERIMENTAL
Intervention: Data collected at 40 weeks
Number of subjects: 429
Study: 35830474

Group type: EXPERIMENTAL
Intervention: sTREM-1
Number of subjects: 805
Study: 35830597

Group type: EXPERIMENTAL
Intervention: COVID-19 with diabetes
Number of subjects: 1000
Study: 35830625

Group type: EXPERIMENTAL
Intervention: Supportive Oncology Care at Home
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no Supportive Oncology Care at Home)
Number of subjects: 20
Study: 35830707

Group type: EXPERIMENTAL
Intervention: Spontaneous breathing trials (SBTs) without added pressure support
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Structured approach including daily assessment of readiness to extubate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Assessment of elevated load and impaired respiratory muscle capacity
Number of subjects: 0
Study: 35830841

Group type: EXPERIMENTAL
Intervention: Lurbinectedin at 3.2 mg/m
Number of subjects: 31
Study: 35830931

Group type: EXPERIMENTAL
Intervention: Arsenic trioxide (ATO) at 1 mg/kg/day, with 11 infusions per cycle of 28 days at a dose of 0.15 mg/kg per infusion.
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Arsenic trioxide (ATO) treatment
Number of subjects: 21
Study: 35830959

Group type: EXPERIMENTAL
Intervention: Joy for All (JfA) devices (1 cat and 1 dog)
Number of subjects: 253

Group type: COMPARATOR
Intervention: Care as usual (control group)
Number of subjects: 253
Study: 35831040

Group type: EXPERIMENTAL
Intervention: Revascularisation in NSTEMI patients
Number of subjects: 1506

Group type: EXPERIMENTAL
Intervention: Revascularisation in UAP patients
Number of subjects: 1506

Group type: COMPARATOR
Intervention: Conservative treatment in UAP patients
Number of subjects: 1506

Group type: EXPERIMENTAL
Intervention: NSTEMI patients
Number of subjects: 1506

Group type: EXPERIMENTAL
Intervention: UAP patients
Number of subjects: 1506
Study: 35831043

Group type: EXPERIMENTAL
Intervention: Multistrip electrode array for continuous electrocorticography monitoring for seizures and CSDs.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subdural electrodes for continuous monitoring.
Number of subjects: 0
Study: 35831051

Group type: EXPERIMENTAL
Intervention: Virtual reality assessment tool 'Spheres & Shield Maze Task' and speech analysis
Number of subjects: 300

Group type: COMPARATOR
Intervention: Traditional measures of impulsivity (Barratt Impulsiveness Scale 11, Urgency, Premeditation, Perseverance, Sensation Seeking, Positive Urgency, Impulsive Behaviour Scale, Iowa Gambling Task, Continuous Performance Test, Stop signal Task, Go/no-go task)
Number of subjects: 300
Study: 35831057

Group type: EXPERIMENTAL
Intervention: Chiropractic care (specific intervention details not provided)
Number of subjects: 0
Study: 35831701

Group type: EXPERIMENTAL
Intervention: AIDA International Registry for Behçet's disease patients
Number of subjects: 290
Study: 35831783

Group type: EXPERIMENTAL
Intervention: MRd (Medication Reconciliation at discharge)
Number of subjects: 0
Study: 35832045

Group type: EXPERIMENTAL
Intervention: Rehabilitation of masticatory function with fixed implant-supported dentures and nutrition education
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 35832177

Group type: EXPERIMENTAL
Intervention: Ozanimod 0.92 mg/day after initial dose escalation for up to 60 months
Number of subjects: 1300

Group type: EXPERIMENTAL
Intervention: Ozanimod 0.92 mg/day
Number of subjects: 1300
Study: 35832286

Group type: EXPERIMENTAL
Intervention: Elevated hsCRP levels (>3 mg/l) in FM patients
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Normal hsCRP levels in FM patients
Number of subjects: 70

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 70
Study: 35832351

Group type: EXPERIMENTAL
Intervention: Eccentric exercise program
Number of subjects: 60

Group type: COMPARATOR
Intervention: Concentric exercise program
Number of subjects: 60
Study: 35832414

Group type: EXPERIMENTAL
Intervention: Wearable sensors and digital alerting systems
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 35832447

Group type: EXPERIMENTAL
Intervention: Camrelizumab 200 mg intravenously every 2 weeks plus apatinib 250 mg orally once daily
Number of subjects: 43
Study: 35832598

Group type: EXPERIMENTAL
Intervention: Coping strategies
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Psychological factors (personality traits, attachment type, traumatic life events)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: PTSD symptoms
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Generalized anxiety
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Anxiety about the COVID-19 pandemic
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Quality of life
Number of subjects: 117
Study: 35833019

Group type: EXPERIMENTAL
Intervention: Alglucosidase Alfa
Number of subjects: 0
Study: 35833116

Group type: EXPERIMENTAL
Intervention: Penpulimab (IgG1 anti-PD-1 antibody)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Penpulimab
Number of subjects: 0
Study: 35833199

Group type: COMPARATOR
Intervention: Mindfulness-Based Relapse Prevention (MBRP) with sham tDCS
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Relapse Prevention (MBRP) with active tDCS
Number of subjects: 0
Study: 35833254

Group type: EXPERIMENTAL
Intervention: COVID-19-related socioeconomic insecurity
Number of subjects: 66

Group type: COMPARATOR
Intervention: Pre-pandemic conditions
Number of subjects: 66
Study: 35833911

Group type: EXPERIMENTAL
Intervention: High frequency VNS
Number of subjects: 439

Group type: COMPARATOR
Intervention: Low frequency VNS
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: VNS stimulation
Number of subjects: 439
Study: 35833913

Group type: COMPARATOR
Intervention: DL-3-n-butylphthalide (24 weeks treatment)
Number of subjects: 3384

Group type: COMPARATOR
Intervention: Aspirin (4 years treatment)
Number of subjects: 3384

Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (clopidogrel plus aspirin)
Number of subjects: 3384
Study: 35834242

Group type: EXPERIMENTAL
Intervention: Remnant cholesterol (remnant-C)
Number of subjects: 10196

Group type: EXPERIMENTAL
Intervention: Visit-to-visit remnant-C variability (logSD)
Number of subjects: 10196

Group type: EXPERIMENTAL
Intervention: Visit-to-visit remnant-C variability (logARV)
Number of subjects: 10196

Group type: EXPERIMENTAL
Intervention: High baseline remnant-C (≥31 mg/dL)
Number of subjects: 10196

Group type: EXPERIMENTAL
Intervention: High baseline remnant-C in LDL-C subgroup (>100 mg/dL)
Number of subjects: 10196

Group type: EXPERIMENTAL
Intervention: High baseline remnant-C in LDL-C subgroup (≤100 mg/dL)
Number of subjects: 10196
Study: 35834315

Group type: EXPERIMENTAL
Intervention: NIATx improvement approach
Number of subjects: 43

Group type: COMPARATOR
Intervention: Traditional product training model
Number of subjects: 43
Study: 35834508

Group type: EXPERIMENTAL
Intervention: Prepectoral breast reconstruction (PBR)
Number of subjects: 81
Study: 35834598

Group type: EXPERIMENTAL
Intervention: Neoadjuvant mFOLFOXIRI chemotherapy
Number of subjects: 106
Study: 35834645

Group type: EXPERIMENTAL
Intervention: Endometrial transcriptome analysis
Number of subjects: 0
Study: 35834646

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 35835008

Group type: EXPERIMENTAL
Intervention: Urate-lowering therapy (ULT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reduction of serum urate (SU)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High serum urate (SU) levels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recent fluctuations in serum urate (SU) levels
Number of subjects: 0
Study: 35835061

Group type: EXPERIMENTAL
Intervention: SOBI003 (3 mg/kg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: SOBI003 (10 mg/kg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: SOBI003 (up to 20 mg/kg during extension study)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: SOBI003 (all doses)
Number of subjects: 6
Study: 35835137

Group type: EXPERIMENTAL
Intervention: Zandelisib 60 mg once daily (intermittent dosing)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Zandelisib 120 mg once daily (intermittent dosing)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Zandelisib 180 mg once daily (intermittent dosing)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Zandelisib (intermittent dosing)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Zandelisib (continuous dosing)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Zandelisib (both dosing schedules)
Number of subjects: 97
Study: 35835342

Group type: EXPERIMENTAL
Intervention: Computer-aided diagnosis (CADx) module for differentiating between adenoma and nonadenoma in unmagnified white-light colonoscopy
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: AI-assisted endoscopist predictions with electronic chromoendoscopy
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: CADx output for resect-and-discard strategy
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Agreement between CADx and histology-based surveillance intervals
Number of subjects: 162
Study: 35835491

Group type: EXPERIMENTAL
Intervention: SCAI staging system parameters (hypotension, hypoperfusion, treatment intensity)
Number of subjects: 3455

Group type: EXPERIMENTAL
Intervention: Systolic blood pressure, lactate level, alanine transaminase level, systemic pH
Number of subjects: 3455

Group type: EXPERIMENTAL
Intervention: Baseline and maximum SCAI stages
Number of subjects: 3455
Study: 35835495

Group type: EXPERIMENTAL
Intervention: Non-Hispanic Black individuals
Number of subjects: 436

Group type: COMPARATOR
Intervention: Hispanic individuals
Number of subjects: 436
Study: 35835523

Group type: EXPERIMENTAL
Intervention: Increased visceral fat and total body fat
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Metabolic factors
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Clinical hand OA
Number of subjects: 306
Study: 35835611

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg Q3W for 35 cycles
Number of subjects: 84
Study: 35835615

Group type: EXPERIMENTAL
Intervention: Generic Database (GDB)
Number of subjects: 91000
Study: 35835670

Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 1430

Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring (CGM)
Number of subjects: 1430

Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 1430
Study: 35835738

Group type: EXPERIMENTAL
Intervention: Antibody-dependent phagocytosis of ring-infected erythrocytes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antibody-dependent phagocytosis of uninfected erythrocytes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surface proteomic analysis revealing merozoite proteins (erythrocyte binding antigen-175 and -140)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Competition phagocytosis assays
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Targeting ring-stage parasites
Number of subjects: 0
Study: 35836289

Group type: EXPERIMENTAL
Intervention: Prenatal Distress Questionnaire (PDQ)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Cortisol measurements from maternal hair strands
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Differentiated methylation regions (DMR) related to maternal stress measures PDQ and cortisol
Number of subjects: 114
Study: 35837099

Group type: EXPERIMENTAL
Intervention: Radiation therapy (RT)
Number of subjects: 186
Study: 35837200

Group type: EXPERIMENTAL
Intervention: Dose-escalated proton therapy with elective nodal irradiation (40.5 GyRBE in 18 fractions followed by 22.5 GyRBE boost); Oral capecitabine (1,000 mg twice daily) during treatment
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Dose-escalated proton therapy with elective nodal irradiation
Number of subjects: 15
Study: 35837409

Group type: EXPERIMENTAL
Intervention: Butantan-DV vaccine
Number of subjects: 40
Study: 35837483

Group type: EXPERIMENTAL
Intervention: Hyperventilation (HV) during preoperative DC-EEG measurement
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Induction of Anesthesia (IOA)
Number of subjects: 15
Study: 35838207

Group type: EXPERIMENTAL
Intervention: Antitumor treatment (surgery, radiotherapy, chemotherapy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antiepileptic drug (AED) treatment (levetiracetam)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Potential add-on AEDs (lacosamide, perampanel, valproic acid)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Benzodiazepines via nonoral administration routes
Number of subjects: 0
Study: 35838424

Group type: EXPERIMENTAL
Intervention: COVID-era cohort
Number of subjects: 2

Group type: COMPARATOR
Intervention: Pre-COVID-era cohort
Number of subjects: 2
Study: 35838761

Group type: EXPERIMENTAL
Intervention: myFAMI intervention (smartphone app with triggered nurse communication)
Number of subjects: 1800
Study: 35838993

Group type: EXPERIMENTAL
Intervention: 1.0 mg/kg 1% propofol (group P: n = 30)
Number of subjects: 113

Group type: COMPARATOR
Intervention: No propofol administration (group C: n = 83)
Number of subjects: 113
Study: 35839001

Group type: EXPERIMENTAL
Intervention: New dispatcher-assisted basic life support training program
Number of subjects: 10127

Group type: COMPARATOR
Intervention: Control group (22 districts without the new training program)
Number of subjects: 10127
Study: 35839129

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 35839426

Group type: EXPERIMENTAL
Intervention: Postconsolidation immunotherapy including dinutuximab, granulocyte-macrophage colony-stimulating factor, and interleukin-2
Number of subjects: 1183
Study: 35839786

Group type: EXPERIMENTAL
Intervention: Lisocabtagene maraleucel
Number of subjects: 61
Study: 35840448

Group type: EXPERIMENTAL
Intervention: Axillary reverse mapping (ARM) using near-infrared (NIR) fluorescence imaging with indocyanine green dye during ALND
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Axillary reverse mapping (ARM) using near-infrared (NIR) fluorescence imaging
Number of subjects: 119
Study: 35840506

Group type: EXPERIMENTAL
Intervention: Low second trimester resting energy expenditure (REE)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Fat-free mass, energy intake (EI), physical activity (PA), and REE
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: High energy intake (EI)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Fat-free mass and physical activity (PA)
Number of subjects: 26
Study: 35840541

Group type: EXPERIMENTAL
Intervention: Exercise Training (ET)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 158
Study: 35840573

Group type: EXPERIMENTAL
Intervention: Amcenestrant 20-600 mg QD
Number of subjects: 16
Study: 35840753

Group type: EXPERIMENTAL
Intervention: Roche PD Mobile Application v2
Number of subjects: 316
Study: 35840898

Group type: EXPERIMENTAL
Intervention: Geriatric Service Hub (GSH) programme
Number of subjects: 0

Group type: COMPARATOR
Intervention: Propensity score-matched comparator group
Number of subjects: 0
Study: 35840912

Group type: EXPERIMENTAL
Intervention: Short-course preoperative radiotherapy (5 Gy × 5 days) and pembrolizumab (4 injections starting on the same day and on weeks 4, 7, and 10)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Short-course preoperative radiotherapy (5 Gy × 5 days) and pembrolizumab
Number of subjects: 25
Study: 35840942

Group type: EXPERIMENTAL
Intervention: Physiotherapy students
Number of subjects: 1154

Group type: COMPARATOR
Intervention: All other NMAHP students
Number of subjects: 1154
Study: 35840949

Group type: EXPERIMENTAL
Intervention: hrHPV self-testing as the primary screening test
Number of subjects: 0
Study: 35841019

Group type: EXPERIMENTAL
Intervention: Shared Decision Making-Renal Supportive Care (SDM-RSC) intervention
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Advance Care Planning (ACP) conversations
Number of subjects: 60
Study: 35841032

Group type: EXPERIMENTAL
Intervention: Diaphragm function assessment using ultrasound, magnetic stimulation, and balloon catheter-based recordings in patients with dyspnea on exertion.
Number of subjects: 10

Group type: COMPARATOR
Intervention: Matched controls (not specified how many or their characteristics).
Number of subjects: 10
Study: 35841038

Group type: EXPERIMENTAL
Intervention: VCP disease patients with confirmed VCP variants
Number of subjects: 106
Study: 35841049

Group type: EXPERIMENTAL
Intervention: 12-lead Holter ECGs
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: NASA Task Load Index
Number of subjects: 20